Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 63323-450

21 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 63323-450). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pemet-struc-01.jpg (Pemet Struc 01)

Pemet-struc-01.jpg (Pemet Struc 01)
Chemical structure of pemetrexed disodium, the active ingredient in Pemetrexed injection. The diagram shows the molecular arrangement including sodium atoms attached to key functional groups.*
FDA Label Image

Pemet-img-01.jpg (Pemet Img 01)

Pemet-img-01.jpg (Pemet Img 01)
A survival curve chart depicting overall survival percentage on the vertical axis and time in months on the horizontal axis. It compares two treatment arms labeled P+PC and PC, showing their survival trends over a period up to 42 months, with number at risk data presented below the graph.*
FDA Label Image

Pemet-img-02.jpg (Pemet Img 02)

Pemet-img-02.jpg (Pemet Img 02)
A survival probability curve graph comparing two treatment groups labeled Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The x-axis represents survival time in months (up to 30 months), and the y-axis shows survival probability from 0 to 1. The graph includes a table below showing numbers of patients at risk at different time points for both groups.*
FDA Label Image

Pemet-img-03.jpg (Pemet Img 03)

Pemet-img-03.jpg (Pemet Img 03)
This Kaplan-Meier survival curve compares overall survival probability over time (in months) for two patient groups: those treated with Pemetrexed plus Cisplatin and those treated with Gemcitabine plus Cisplatin. The graph includes a table showing the number of patients at risk at intervals throughout the study period up to 30 months.*
FDA Label Image

Pemet-img-04.jpg (Pemet Img 04)

Pemet-img-04.jpg (Pemet Img 04)
A survival probability plot comparing patients treated with Pemetrexed plus Cisplatin and Gemcitabine plus Cisplatin over a survival time span of up to 30 months. The x-axis represents survival time in months, and the y-axis shows survival probability, with an accompanying patient-at-risk table below the curves.*
FDA Label Image

Pemet-img-05.jpg (Pemet Img 05)

Pemet-img-05.jpg (Pemet Img 05)
A survival curve chart showing survival probability over time in months, comparing patients treated with Pemetrexed versus placebo. The X-axis represents survival time up to 42 months, and the Y-axis shows survival probability from 0.0 to 1.0. The chart includes a legend distinguishing Pemetrexed and placebo treatment groups and a table of patients at risk over time intervals.*
FDA Label Image

Pemet-img-06.jpg (Pemet Img 06)

Pemet-img-06.jpg (Pemet Img 06)
A survival probability curve comparing Pemetrexed injection versus placebo over time in months. The graph plots survival probability on the vertical axis against survival time in months on the horizontal axis, including a risk table showing patient numbers at various time points for each group.*
FDA Label Image

Pemet-img-07.jpg (Pemet Img 07)

Pemet-img-07.jpg (Pemet Img 07)
A survival curve chart comparing survival probability over time (in months) between patients treated with Pemetrexed and a placebo. The x-axis represents survival time in months, and the y-axis represents survival probability. The chart includes a table of patients at risk at various time points for each group.*
FDA Label Image

Pemet-img-08.jpg (Pemet Img 08)

Pemet-img-08.jpg (Pemet Img 08)
A survival probability Kaplan-Meier curve comparing Pemetrexed and placebo over a 36-month period. The graph shows survival time in months on the x-axis and survival probability on the y-axis, with separate lines for Pemetrexed and placebo, indicating patient survival trends over time.*
FDA Label Image

Pemet-img-09.jpg (Pemet Img 09)

Pemet-img-09.jpg (Pemet Img 09)
Survival curve chart comparing survival probability over time in months for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The chart includes a legend and a table showing the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Pemet-img-10.jpg (Pemet Img 10)

FDA Label Image

Pemet-img-11.jpg (Pemet Img 11)

FDA Label Image

Pemet-img-12.jpg (Pemet Img 12)

FDA Label Image

Pemet-label-01.jpg (Pemet Label 01)

Pemet-label-01.jpg (Pemet Label 01)
Pemetrexed for Injection, USP 100 mg per vial powder label for intravenous use only. The label indicates it is a cytotoxic agent and a single-dose vial, manufactured by Fresenius Kabi USA, LLC. Storage instructions specify storing powder at 20° to 25°C and room temperature for reconstituted solutions.*
FDA Label Image

Pemet-label-02.jpg (Pemet Label 02)

Pemet-label-02.jpg (Pemet Label 02)
Label for Pemetrexed injection, USP, 100 mg per vial, powder, lyophilized, for solution. The label states it is for intravenous use only and cautions that it is a cytotoxic agent. It includes storage instructions and reconstitution directions. The label shows the Fresenius Kabi USA, LLC logo and website, with NDC 63323-134-10 and a barcode.*
FDA Label Image

Pemet-label-03.jpg (Pemet Label 03)

Pemet-label-03.jpg (Pemet Label 03)
Label for Pemetrexed for Injection, USP 500 mg per vial, a lyophilized powder for intravenous use. The label indicates it is a single-dose vial and a cytotoxic agent. Manufactured by Fresenius Kabi USA, LLC, the label includes storage instructions and the NDC 63323-450-50.*
FDA Label Image

Pemet-label-04.jpg (Pemet Label 04)

Pemet-label-04.jpg (Pemet Label 04)
Label for Pemetrexed for Injection, USP, 500 mg per vial, lyophilized powder for intravenous use. The single-dose vial is a cytotoxic agent and is manufactured by Fresenius Kabi USA, LLC. Instructions for storage, reconstitution, and handling are included, with a barcode and NDC number 63323-450-50.*
FDA Label Image

Pemet-label-05.jpg (Pemet Label 05)

Pemet-label-05.jpg (Pemet Label 05)
Label for Pemetrexed for Injection, USP 750 mg per vial, a lyophilized powder for intravenous use. The label notes it is a cytotoxic agent, single-dose vial, prescription only. Manufactured by Fresenius Kabi in Lake Zurich, IL. Storage instructions specify 20° to 25°C controlled room temperature.*
FDA Label Image

Pemet-label-06.jpg (Pemet Label 06)

Pemet-label-06.jpg (Pemet Label 06)
Pemetrexed for Injection, USP 750 mg per vial, injection powder, lyophilized, for intravenous use. The label includes warnings for cytotoxic agent and storage instructions. It is a single-dose vial distributed by Fresenius Kabi USA, LLC, featuring usage cautions and reconstitution instructions on the packaging.*
FDA Label Image

Pemet-label-07.jpg (Pemet Label 07)

Pemet-label-07.jpg (Pemet Label 07)
Label for Pemetrexed for Injection, USP, 1 gram per vial. The product is a single-dose vial intended for intravenous use only. It includes a caution that it is a cytotoxic agent. The label also provides storage instructions and manufacturer information for Fresenius Kabi, Lake Zurich, IL.*
FDA Label Image

Pemet-label-08.jpg (Pemet Label 08)

Pemet-label-08.jpg (Pemet Label 08)
Pemetrexed for Injection, USP 1 gram per vial, lyophilized powder for intravenous use, displayed on a multi-panel label. The label includes warnings for cytotoxicity, storage instructions, and reconstitution directions. Manufactured by Fresenius Kabi USA, LLC, it is presented as a single-dose vial with Rx only status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.